- Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 8, 2024
- Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress
- Arcturus Therapeutics to Present at the Barclays 26th Annual Global Healthcare Conference
- Arcturus Therapeutics Receives Orphan Medicinal Product Designation from the European Commission (EC), for ARCT-032, for the Treatment of Cystic Fibrosis
- Arcturus Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on March 7, 2024
More ▼
Key statistics
As of last trade, Arcturus Therapeutics Holdings Inc (ARCT:NMQ) traded at 27.05, 54.39% above the 52 week low of 17.52 set on Nov 13, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 27.06 |
---|---|
High | 27.90 |
Low | 26.73 |
Bid | 27.02 |
Offer | 27.12 |
Previous close | 27.27 |
Average volume | 573.09k |
---|---|
Shares outstanding | 26.92m |
Free float | 24.56m |
P/E (TTM) | -- |
Market cap | 733.98m USD |
EPS (TTM) | -1.16 USD |
Data delayed at least 15 minutes, as of May 06 2024 16:44 BST.
More ▼